Singeap AM, Minea H, Stafie R, Stanciu C, Trifan A. Towards precision care: Fluctuations in albumin and fibrinogen as noninvasive predictors of endoscopic outcomes in Crohn’s disease. World J Gastrointest Endosc 2025; 17(5): 105365 [DOI: 10.4253/wjge.v17.i5.105365]
Corresponding Author of This Article
Horia Minea, MD, PhD, Assistant Professor, Department of Gastroenterology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Street, Iasi 700115, Romania. horia.minea@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. May 16, 2025; 17(5): 105365 Published online May 16, 2025. doi: 10.4253/wjge.v17.i5.105365
Towards precision care: Fluctuations in albumin and fibrinogen as noninvasive predictors of endoscopic outcomes in Crohn’s disease
Ana-Maria Singeap, Horia Minea, Remus Stafie, Carol Stanciu, Anca Trifan
Ana-Maria Singeap, Horia Minea, Remus Stafie, Carol Stanciu, Anca Trifan, Department of Gastroenterology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi 700115, Romania
Ana-Maria Singeap, Horia Minea, Remus Stafie, Carol Stanciu, Anca Trifan, Institute of Gastroenterology and Hepatology, “St. Spiridon” University Hospital, Iasi 700111, Romania
Author contributions: Singeap AM designed the editorial; Minea H and Stafie R wrote the paper; Stanciu C and Trifan A revised the paper for important intellectual content; and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Horia Minea, MD, PhD, Assistant Professor, Department of Gastroenterology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Street, Iasi 700115, Romania. horia.minea@yahoo.com
Received: January 20, 2025 Revised: March 29, 2025 Accepted: April 17, 2025 Published online: May 16, 2025 Processing time: 112 Days and 18 Hours
Abstract
In this article, we comment paper by Wang et al published recently. The study represents a notable step in the pursuit of precision medicine for inflammatory bowel diseases, offering valuable insights into the potential of noninvasive biomarkers for Crohn’s disease (CD) management. This article highlights the significance of the findings, particularly the identification of albumin and fibrinogen amplitude changes as effective, noninvasive biomarkers for predicting endoscopic improvement in CD. The authors introduce a reliable nomogram model, constructed through careful logistic regression analyses, that demonstrates high predictive accuracy across training, internal validation, and external validation cohorts. With further validation through calibration and decision curve analyses, this model shows its clinical relevance and applicability. By incorporating albumin and fibrinogen fluctuations into clinical decision-making, this model addresses a critical gap in noninvasive monitoring tools for CD, offering a practical, patient-centered alternative to guide therapeutic strategies. These findings not only validate the utility of the model but also pave the way for broader integration of biomarker-driven decision-making in the management of CD. This article discusses the broader implications of these advancements, emphasizing their potential to refine patient care and improve outcomes in CD management.
Core Tip: This article highlights the significance of a study by Wang et al, which identifies fluctuations in albumin and fibrinogen as noninvasive biomarkers for predicting endoscopic improvement in Crohn’s disease. By introducing a validated nomogram model with high predictive accuracy, the study offers a practical, patient-centered alternative to invasive monitoring methods. These findings underscore the potential of biomarker-driven decision-making to refine therapeutic strategies, enhance patient care, and advance precision medicine in Crohn’s disease management.
